Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, ...

2 spike compared with either XBB.1.5 or the ancestral WA1 spike. This finding highlights the relevance of closely monitoring the immune evasiveness of emerging variants to expedite the development and ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

A nasal vaccine for COVID-19—based on technology developed at Washington University in St. Louis—is poised to enter a phase 1 ...

With the rise of omicron came the fall of long-lasting protection from reinfection with the pandemic coronavirus SARS-CoV-2, ...

SARS-CoV-2 spike RBD IgG ELISA was carried out as previously described13 14 (online supplemental methods). The primary analysis was to compare the relationship between microbiome profile and immune ...

With a substantial number of mutations in its Spike protein, the SARS-CoV-2 Omicron variant is prone to immune evasion and led to the reduced efficacy of approved vaccines. Thus, emerging variants ...

The COVID-19 vaccine confers protection against the development of post-COVID-19 conditions, particularly during the Delta and Omicron eras.